Evidence map›Paper›PMID 42032486›Full record

ArticleBMC infectious diseases2026

Burden of herpes zoster and postherpetic neuralgia in Jinan, China: incidence, recurrence, and direct medical costs, 2018-2023, a population-based retrospective cohort study.

Zemei Zhou, Xiaoqi Wang, Shuai Meng, Lin Tang, Siyu Liu, Qianqian Liu, Xiaoxue Liu, Zundong Yin, Chong Liu, Fuzhen Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zemei ZhouNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China.
Xiaoqi WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China.
Shuai MengJinan Health and Wellness Development Center, Jinan, Shandong, China.
Lin TangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China.
Siyu LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China.
Qianqian LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China.
Xiaoxue LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China.
Zundong YinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China.
Chong LiuJinan Health and Wellness Development Center, Jinan, Shandong, China. 40534211@qq.com.
Fuzhen WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China. vvpd@chinacdc.cn.

Funding

Beijing Natural Science Foundation Committee L244078
6 · The paper itself

Abstract

backgroundHerpes zoster (HZ) and postherpetic neuralgia (PHN) cause substantial clinical and economic burdens, especially in older adults, yet real-world data from China are limited.

methodsUsing the Jinan Regional Health Information Platform, we conducted a population-based retrospective cohort study (2018-2023) to estimate HZ and PHN incidence (per 1,000 person-years [PY]), recurrence rates, and direct medical costs and factors associated with costs.

resultsThe study included 166,869 patients with HZ. The coverage-adjusted incidence of HZ was 6.80 per 1,000 person-years (PY) overall and ranged from 9.68 per 1,000 PY in the 50-59-year age group to a peak of 16.48 per 1,000 PY in the 70-79-year age group. PHN occurred in 14.2% of HZ patients. The overall coverage-adjusted incidence of PHN was 0.94 per 1,000 PY. HZ recurrence occurred in 0.87% of patients, corresponding to an incidence of 4.26 per 1,000 PY. A total of 72.9% of patients were included in the cost analyses. Median annual costs per patient were CNY 155.2 (interquartile range [IQR]: 50.3-533.1) overall, CNY 126.7 (IQR: 44.4-365.6) for outpatients and CNY 6,290.2 (IQR: 4,038.4-9,093.6) for inpatients. Higher costs were associated with older age, PHN, healthcare facility type, more frequent visits, and length of stay.

conclusionsHZ and PHN impose substantial epidemiological and economic burdens in Jinan, with incidence increasing with age, a persistent risk of recurrence, and costs influenced by demographic and healthcare-related factors.

Indexed as

Cost of IllnessHealth Care CostsHerpes ZosterNeuralgia, PostherpeticAdolescentAdultAgedAged, 80 and overChinaFemaleHumansIncidenceMaleMiddle AgedRecurrenceRetrospective StudiesDirect medical costsHerpes zosterIncidencePostherpetic neuralgiaRecurrence

Identifiers

PMID42032486
PMCPMC13344021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.